SUMMARY The effect of two doses ofcimetidine, 400 mg at night and 400 mg bd, on the protection of indomethacin (50 mg tid) induced mucosal damage was evaluated in a double blind study in patients with acute musculoskeletal disorders. Endoscopic mucosal lesions were scored before and after five to seven days oftreatment. One hundred and ninety one patients were endoscoped before the trial, 34 (17.8%) had >one erosion and were not recruited. Forty patients were excluded for noncompliance, or lost to follow up. At the second endoscopy, oesophageal, and fundic damage was negligible. Gastric and duodenal lesion score in patients treated with cimetidine 400 mg bd: 2.7 (0.5) (SE); n=42) was significantly lower (p<00122) than in placebo treated patients: 6-1 (0.9) (n=50) or in patients treated with cimetidine 400 mg at night 7.1 (0.8) (n=21). Cimetidine 400 mg bd provided significant protection for the duodenum, but its protection of antral mucosa did not reach statistical significance. There was no correlation between upper gastrointestinal symptoms and endoscopic findings.
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Non-steroidal anti-inflammatory drugs (NSAIDs) have become an integral part of the therapy of rheumatologic disorders. Non-steroidal antiinflammatory drugs are now the most widely prescribed of all drugs when grouped by generic categories, not including aspirin, the most commonly used of all drugs, and the prototype of NSAIDs. ' Non-steroidal anti-inflammatory drugs damage the gastroduodenal mucosa as has shown endoscopically and by faecal blood loss studies. ' Endoscopic examination was done before starting treatment. A normal gastroduodenal mucosa was required in order to be enrolled in the study. All the qualified subjects received indomethacin 150 mg daily in three divided doses with meals and were randomised into one of three groups in a double blind manner to receive either cimetidine 400 mg hs, cimetidine 400 mg bid, or placebo. Tablets containing 400 mg cimetidine or matching placebo were packed in vials of 16 tablets each. Patients were given two vials and were instructed to take one tablet from one vial before breakfast and from the other vial at bedtime. Each patient was also asked to record on a diary card the daily frequency and severity: none=0; mild=1; moderate=2; severe=3, of the following symptoms: abdominal pain, discomfort, heartburn, nausea, and vomiting. In all patients medication was started not later than 10 hours after the endoscopy.
The duration of treatment was 14 days. Patients had a second endoscopy on the fifth to seventh day of therapy: the appearance of the fundus, antrum, and duodenum were sequentially and separately noted. The presence of erythema, haemorrhages, erosions, or ulcers were recorded and scored: erythema: none=0, mild= 1, moderate/severe=2; haemorrhages: none=0, 1=1, 2-5=2, 6-20=3, >20=4; erosions: none=0, 1=2, 2-5=4, 6-20=6, >20=8; ulcers: none=0, 1 One hundred and ninety one patients with acute musculoskeletal disorders were referred by orthopaedic surgeons to the study. They were all endoscoped. Thirty four patients were found to have abnormal mucosa in the stomach or duodenum. These patients were not eligible for the study.
Of the 157 patients enrolled in the study, 40 patients were excluded because of lost follow up or non-compliance with either indomethacin or with the coded medication. The musculoskeletal disorders of the patients who concluded the trial are detailed in Table 1 .
An interim analysis was performed when 73 patients were eligible for analysis after the second endoscopy: 30 in the placebo, 21 in the cimetidine 400 mg hs and 22 patients in the cimetidine 400 mg bid treatment group. This analysis revealed that there was no difference in total lesion score in patients treated with cimetidine 400 mg hs or placebo: 7.1 (0-8) (SE) and 9-1 (4.8) respectively and therefore the cimetidine 400 mg hs dose was omitted when further recruitment took place. The double blindness between the remaining two treatment groups, however, was maintained. There was no difference in the sex or age distribution among patients in the three treatment groups ( Table  1) . The mean total damage score of all gastric and duodenal lesions in the placebo treated patients -6-1 nausea, and vomiting -was similar in the three ents with acute musculoskeletal condition were treated treatment groups (Table 2 ). In those patients who lindomethacin 50 mg tid together with cimetidine 400 mg also concluded the second week of treatment with t00 mg bid, orplacebo. Endoscopy was done afterfive to cimetidine 400 mg bid, a trend towards reduction in pn days. The presence oferythema, haemorrhages ions, and ulcers in stomach and duodenum was scored as global symptom score was noted: 0h78 (0-88) (SD) *ribed in Methods. Results are mean (SE). Points n=28) as opposed to 0a96 (0.83) in the same subjects esent scores ofindividual subjects. *Significantly after the first week. There was also no correlation 'rentfrom placebo p<0-0122 (Mann-Whitney U test).
between upper gastrointestinal symptoms and endo- the treatment the
Discussion
Numerous new NSAIDs have been developed with the two-fold objective of producing greater antiinflammatory effect than aspirin with less gastrointestinal toxicity. A significant degree of gastric mucosal haemorrhage and ulceration was shown, however, in patients and in normal volunteers taking these agents even for brief periods of time.2315 Differences in the degree of injury do exist among different drugs2 and for each drug, the severity of mucosal damage is dose dependent.2 Indomethacin in doses of 100 to 150 mg a day has been reported to cause a similar degree of mucosal injury to that induced by aspirin 3600 mg a day.`6 In the present study, the high dose of indomethacin was used with the assumption that protection provided against this dose will definitely be effective against a lower dose. Indomethacin has been shown to induce more gastrointestinal side effects such as nausea, epigastric pain, heartburn, and abdominal discomfort than the newer NSAIDs. 6 Several studies evaluated whether coadministration of NSAIDs and other drugs, such as H2 antagonists, antacids, prostaglandins and their synthetic analogues would minimise NSAIDs induced gastrointestinal damage."-'4 [17] [18] [19] [20] [21] Cimetidine, has been reported to have a protective effect on NSAID induced mucosal damage, determined endoscopically or through analysis of faecal blood loss. " '-4 Most of these studies were carried out in experimental animals, however, or only in a small number of subjects and in patients taking aspirin chronically. [11] [12] [13] [14] Indomethacin 150 mg a day when administered for five to seven days induced significant gastroduodenal injury in about 50% of the subjects. Non-steroidal anti-inflammatory drugs are usually believed to induce mainly gastric damage. The results obtained in the present study in the placebo treated patients clearly show that in indomethacin treated patients duodenal mucosal injury is as common and as severe as gastric mucosal injury. In a similar way we have recently shown in a retrospective study that duodenal injury induced by other NSAIDs is also as common as the gastric damage.22
Upper gastrointestinal symptoms are regarded by many as an indication of the presence of gastroduodenal mucosal injury. The results reported herewith, clearly indicate that there is no correlation between upper gastrointestinal symptoms and the presence or severity of objective endoscopically proven mucosal damage. Moreover, cimetidine, when coadministered in a dose which afforded effective mucosal protection, did not affect the subjective symptoms.
Seventeen per cent of the subjects without any gastrointestinal complaint and therefore with presumably normal mucosa were found on the first endoscopy before inclusion in the study to have gastroduodenal mucosal damage. Most of these subjects had erosions in the stomach and/or duodenum but three had duodenal ulcer, one gastric ulcer, and one ulcerated leiomyoma. This finding concurs with recent observation of Akdamar et al12 and Woltjen et al24, who found an even higher incidence of mucosal lesions in normal asymptomatic volunteers.
In addition to suppression of mucosal prostanoids'9 indomethacin stimulate basal gastric acid secretion,' and like aspirin may impair acid induced bicarbonate secretion,' which can definitely contribute to the pathogenesis of the mucosal injury induced by this drug. The mechanism whereby protection is afforded by cimetidine can be mediated through its antisecretory effect.7 By raising the intragastric pH, cimetidine given twice daily could decrease the lipid solubility of indomethacin. As indomethacin's pKa is 4-5 at pH much above 4 5 more than half of the indomethacin would become ionised and therefore be not available for direct absorption into the gastroduodenal mucosa by lipid solubility. Cimetidine protective effect on the gastric mucosal barrier8 and its stimulation of gastric prostanoid synthesis,27 may also explain its protection against the indomethacin induced damage. The lack of protection provided by cimetidine 400 mg hs suggests that cimetidine's antisecretory effect is the main property responsible for its protection against NSAIDs induced damage. 
